Half year pro ad report 2019: Glaxo, J&J and Pfizer topped the list of biggest individual spenders
Marketers of cancer drugs spent far more than marketers of drugs for other conditions.
Commercial
Pro ad report 2018: Advertising remained flat year over year
While advertising in medical journals remained basically flat, the biggest players increased their volume of ad pages.
Drug marketing’s collision course with pricing
A combination of profound skepticism of the industry and generous funding for health communications is a perfect storm. Is there a way through?
Clarity in DTC TV ad drug pricing
Belle Frank is chief strategy officer, global health practice at VMLY&R.
Co-pay accumulators: A force to be reckoned with in 2019
Experts predict the controversial tactic will be deployed far more widely this year, significantly impacting manufacturers — and, whether or not they realize it yet, patients.
Focus on drugs’ cost may prevent their discovery
Breakthrough drugs will eventually be more affordable, but a misplaced focus on their cost may prevent them from being discovered at all.
PhRMA spent nearly 10 times 2016’s sum on advertising last year
The group’s lobbying spend also doubled in 2017 as the Trump administration bore down on drug prices.
CEO: Marketing plan for anti-epileptic aims to distinguish it from sea of other cannabis drugs
A central component of the Epidiolex marketing strategy involves highlighting the drug’s efficacy and safety profile, not its precedent-setting CBD component.
Science behind Nobel winners spawned one of the biggest marketing duels in pharma history
The war on cancer took a big turn with the birth of checkpoint inhibitors. Laura Entis explores their scientific and commercial impact, the unanswered questions, and what’s next for this enormously successful group of immunotherapies.
A timeline of key moments in the development of checkpoint inhibitors
Immunotherapy’s modern era has been characterized by a tremendous amount of scientific and regulatory activity. Trace the road to the Nobel.
Want to read more?
Please login or register first to view this content.
